This study tests a new drug called brenetafusp (IMC-F106C) in adults with advanced cancers that have a specific marker called PRAME. The drug is designed to help the immune system find and attack cancer cells. The trial includes about 410 participants and aims to check safety and…
Phase: PHASE1, PHASE2 • Sponsor: Immunocore Ltd • Aim: Disease control
Last updated May 14, 2026 12:06 UTC